Member Info for Ivyspivey

Yep all well and no we missed it again as had a few other things going on.

But sun shining,market showing a lot of green shoots so overall can’t complain and hope things are going well your side.

Hi Bermuda.I could not access full job description but the point you raised is very valid.

It really does imo make a difference to whether the position is additional or as a replacement in terms of trying to work out the strategic way forward

Hi CW/Sci as AP is head of manu with lots of CMC experience and they also have Aleksandra as well so if it is an additional person then I think that is very significant for gives a steer as to for the future.

New advert looks interesting but crucial point to me.

Is it an additional position or does it replace Adrian Parry’s role.

Thanks for your thoughts Burble and makes sense.

Does the current agreement with PJ only include the Stratis so if they went with ID they may need another agreement to cover the Tropis though am sure they have had discussions.

Not sure when the pre clinical ID work was done as they made the decision late and presume they did not just go off the Covidity work.

I Pad,

Don’t know why it was today but good they want to communicate with SH and good opportunity to ask questions.

Can’t understand why anyone expected news as seemed clear from the Linked in update about the meeting that nothing of material news was going to be included and the line up is more Commercial than Scientific.

The poster at AACR is hopefully very different and I would expect a trial update there with new info which I I will be much more relevant.

Scancell CEO, Phil L'Huillier L’Huillier, and CFO, Sath Nirmalananthan, will host a live #Investor presentation at 2:30PM BST on Thursday, 24 April

This will be a general update on recent progress, including our landmark #partnership with the NHS Vaccine Launch Pad to fast-track patients into the fourth cohort of our ongoing Phase 2 SCOPE trial in advanced #melanoma.

This event is open to all existing and potential shareholders. Questions may be submitted pre-event via the Investor Meet Company dashboard or at any time during the event.

📅 Register here: https://lnkd.in/eZayR54B

#Biotech #CancerCare #Immunology #CancerResearch #Webcast

Just to clarify when I said use of Tropis with SCLP I mean from Cohort 2 so with SCIB 1 as obviouslyvwe have no results from Cohort 4.

Again I presume Tropis was used in Cohort 2 but SCLP licence is only with Stratis as far as I recall so any other info confirming my understanding would be great.

Morning and thanks TF so wanted to explain my thoughts but welcome any comments to clarify the position.

Pharmajet or PJ have two delivery systems of relevance the Stratis IM and the Tropis ID.The last update involved Stratis and quoted SCLP and Evaxion.

https://pharmajet.com/pharmajet-poster-presentation-at-cancer-immunotherapy-conference-highlights-how-needle-free-technology-is-enhancing-oncology-solutions/

So I think they are using Stratis in Cohort 3 and presume Tropis in Cohort 4.

Also noticed that the two more recent publications from PJ involve use of Tropis on other Vaccinations so Covid and Polio Vax so I wondered if moving forward they were concentrating on ID rather than IM ( understanding that Tropis has a CE Mark and WHO Approval whereas Stratis has these plus FDA device Clearance.

I suppose I was trying to work out the true motivation behind the whole decision to set up Cohort 4 which as we know was not in the original plan.

Anyway the PJ poster next week at the WVC which Bermuda highlighted on 23rd used delivery systems in plural so I wondered if it was going to include any Tropis results re SCLP and that was the bit I saw as possibly be very relevant here.

Plus we also have the SCLP update on AACR and Investor Meet so next week could be very interesting.

Enjoy rest of w/ end

Https://www.investegate.co.uk/announcement/rns/scancell-holdings--sclp/scancell-to-present-at-2025-aacr-annual-meeting-/8806699

Thanks for all insights and don’t want to make any political points but seems sensible to take action now as we can’t predict any tax changes which may be made in the future.However better to make these decisions when tax implications are known as we know the fiscal situation more likely to take a turn for the worse

Evening very unlikely imo as I think Burbles initial comments are much more likely to ring truegiven his insight into how the Biopharma industry works

Thanks to Rats for letting us know but more importantly the board is united in wishing you all the best in your current situation.

Keep punching like many have said and sincere best wishes

Thanks Chester

FAO Burble or anyone.

What are peoples thoughts on why SCLP have decided to run Cohort 4?

It seemed to be decided at a later stage and not part of the original plan so why the apparent change of heart.

Interested in peoples thoughts

Good summary Burble and you make an interesting point about accelerated stability data and the pathway beyond current trial results

Heather Shaw previous comments

Dr Heather Shaw, Medical Oncologist, University College Hospital, London, UK commented: “Based upon the

emergent striking PFS, DCR and ORR results from cohort 1 so far and the lack of toxicity relating to the agent itself, SCIB1

is a promising product that would be a significant addition to ipilimumab and nivolumab and would be an important

step forward in improving first line therapy for advanced melanoma patients. “

Cohort 2, investigating SCIB1 in combination with pembrolizumab, has recruited 9/43 patients and cohort 3,

investigating the next generation, iSCIB1+ in combination with ipilimumab and nivolumab has recruited 33/43 patients.

The iSCIB1+ cohort has predominantly recruited the non HLA.A2 matched patients as these patients are being enrolled

in cohort 1. Once recruitment in cohort 1 is complete, HLA.A2 patients will be recruited to complete cohort 3 to give a

representative sample of the advanced melanoma patient population. It is anticipated that all cohort 3 patients will

reach week 25 during H2 2025. This will allow us to select the best vaccine for our planned phase 2/3 randomised,

adapted registration trial.

Https://www.express.co.uk/news/uk/1993653/2024-was-year-of-cancer

Https://www.curetoday.com/view/top-5-cancer-vaccine-stories-from-2024#:~:text=In%20March%202024%2C%20the%20FDA,tube%20or%20primary%20peritoneal%20cancer

Yep JPM is more interesting in Jan as it is easier to get to know who is there and posters much more public.

Plus think a lot of interest in SCLP will come from US so you need to be there.

Even if SCLP don’t go to Jeffries officially would be very surprised if new guy did not go to London as they will get invited and it is a great place to meet and greet and we know his contact list will be decent.

.